Rapid Medical, a company focused on the development of next generation neurovascular devices, has announced that it has received CE mark approval for the TIGERTRIEVER 13. In addition, first patients have been treated successfully with the device.
TIGERTRIEVER, the first-ever adjustable, fully visible clot retriever is designed to treat ischaemic stroke patients. About 1,500 patients have been successfully treated with the TIGERTRIEVER so far, the TIGERTRIEVER 13 is the newest addition of the Tigertriever family. Its default profile is 83% smaller than any other device on the market and it is delivered through a neurovascular microcatheter with a soft distal outer diameter of 1.3Fr. It is designed to recanalise intracranial vessels of 1mm–2.5mm. These medium vessel occlusions (MVO) may account for up to 30% of ischaemic stroke patients and cannot be treated by any other device on the market.
“TIGERTRIEVER 13 is a very important addition to the ischaemic stroke device market,” said René Chapot, Germany. “For the first time ever, we have a tool that is dedicated to more distal occlusions. These occlusions can have a dramatic disabling effect on patients and until now there was little to be done for them. Using the Tigertriever 13 we were able to retrieve clots from an MVO that was not treatable until now.”
Jeffrey Saver, professor of neurology and director of the comprehensive stroke centre at the David Geffen School of Medicine of UCLA, USA, commented on the first clinical experience with the TIGERTRIEVER 13: “We know that endovascular therapy is the best option for large vessel occlusions. The TIGERTRIEVER 13 will further extend this powerful treatment for acute ischaemic stroke to patients with medium vessel occlusions (MVOs).”
Rapid Medical will launch the TIGERTRIEVER 13 in Europe during Q3 2018.